|
|
Third
Wave Technologies (TWTI)

Website:
www.TWT.com
Develops
and markets molecular diagnostic products
Overview
Third Wave Technologies (Nasdaq: TWTI)
develops and markets molecular diagnostic products for various DNA and RNA
analysis applications to clinical, research, and agricultural
customers.
The
company offers a number of products based on its Invader® chemistry for
clinical testing. Third Wave offers in vitro diagnostic kits, and analyte
specific, general purpose, and research use only reagents for nucleic acid
analysis.
The company also develops various DNA and RNA
analysis products for the research and agricultural biotechnology markets.
Its customers include pharmaceutical and biotechnology companies, academic
research centers, and health care providers. The company markets its
products through an internal sales force, as well as collaborative
relationships with pharmaceutical companies and research institutions in the
United States and Europe.
TWTI
Investor Highlights
- Announced that the company
achieved all primary clinical endpoints in the clinical trial for its
human papillomavirus (HPV) tests.
- Reported revenue of $26.3
million for the year ended Dec. 31, 2007, an increase of 25% from 2006.
The company reported research revenue of $4.6 million for 2007. Total
revenues for the year ended Dec. 31, 2007, were $31.1 million.
- Announced the appointment
of Christopher Burton as the company’s
senior vice president of sales and marketing. Mr. Burton, 41, brings
nearly 20 years of selling and marketing experience to his new role at
Third Wave. He joins the company from GE Healthcare.
- Recently announced that
Inverness Medical Iberica, the Spanish affiliate of Inverness Medical
Innovations, will distribute Third Wave’s
HPV high-risk screening test in Spain and Portugal. Inverness Medical
Iberica is a leader in the marketing of diagnostics to assist laboratory
and health care professionals in both preventive and interventional
medicine.
Recent
News and Press Releases
Hologic
to Acquire Third Wave Technologies
Third
Wave Strengthens Core Intellectual Property Portfolio
Third
Wave Reports First-Quarter Financial Results
Third
Wave Completes FDA Submissions for Its Two HPV Products
Third
Wave, DCL Medical Laboratories Form Strategic Partnership
Third
Wave's InPlex(TM) CF Molecular Test Receives FDA Clearance
Third
Wave's HPV Clinical Trial Achieves Primary Clinical Endpoints
Third
Wave Reports Strong Full-Year 2007 Results, Continued Clinical Revenue
Growth
Third
Wave Responds to Court Ruling on Anti-Trust Claims in Digene Suit
Third
Wave Announces First European HPV Distribution Partners
For the latest Quote
and News on TWTI Click
Here.
Three
Month Chart

Contacts
Third Wave Technologies
502 South Rosa Road
Madison, WI 53719
Phone: 608-273-8933
Fax: 608-273-8618
SEC Filings
TWTI filings with the SEC can be found here.
All Fillings are current and the Company is fully reporting.
Disclaimer
SmallCapReview.com
feature stock reports are intended to be stock ideas, NOT recommendations.
Please do your own research before investing. It is crucial that you at
least look at current SEC filings and read the latest press releases.
For continuing coverage of TWTI, please sign up for our free newsletter.
Information contained in this report was extracted from current documents
filed with the SEC, the company web site and other publicly available
sources deemed reliable. For more information see our disclaimer section, a
link of which can be found on our web site. This document contains
forward-looking statements, particularly as related to the business plans of
the Company, within the meaning of Section 27A of the Securities Act of 1933
and Sections 21E of the Securities Exchange Act of 1934, and are subject to
the safe harbor created by these sections. Actual results may differ
materially from the Company's expectations and estimates. The information
provided in this report is not intended for distribution to, or use by, any
person or entity in any jurisdiction or country where such distribution or
use would be contrary to law or regulation or which would subject us to any
registration requirement within such jurisdiction or country.
Copyright
SmallCapReview.com. All rights reserved. SmallCapReview.com is not a
Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out
to be. All materials presented on our web site and individual reports
released to the public through this web site, e-mail or any other means of
transmission are not to be regarded as investment advice and are only
for informative purposes. Before making a purchase or sale of any securities featured
on our web site or mentioned in our reports, we strongly encourage and
recommend consultation with a registered securities representative.
This is not to be construed as a solicitation or recommendation to buy or
sell securities. As with any stock, companies we select to profile involve a
degree of investment risk and volatility. Particularly Small-Caps and OTC-BB
stocks. All investors are cautioned that they may lose all or a portion of
their investment if they decide to make a purchase in any of our profiled
companies. Past performance of our profiled stocks is not indicative of
future results. The accuracy or completeness of the information on our web
site or within our reports is only as reliable as the sources they were
obtained from. The profile and opinions expressed herein are expressed
as of the date the profile is posted on site and are subject to change
without notice. No investor should assume that reliance on the views,
opinions or recommendations contained herein will produce profitable
results. SmallCapReview.com may hold
positions in securities mentioned herein, and may make purchases or sales in
such securities featured on our web site or within our reports. In order to
be in full compliance with the Securities Act of 1933, Section 17(b),
SmallCapReview.com will disclose in it's disclaimer, what, if any
compensation was received for our efforts in researching, presenting
and disseminating this information to our subscriber database and featuring
the report on the SmallCapReview.com web site. SmallCapReview.com
has not been compensated for its efforts in presenting the Third Wave Technologies
profile on its website and distributing it to its
database of subscribers. SmallCapReview.com
may decide to purchase or sell shares on a voluntary basis in the open
market before, during or after the profiling period of this report.
Information presented on our web site and within our reports contain
"forward looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934. Any statements that express or
involve discussions with respect to predictions, expectations, beliefs,
plans, projections, objectives, goals, assumptions or future events or
performance are not statements of historical fact and may be "forward
looking statements." Forward looking statements are based on
expectations, estimates and projections at the time the statements are made
that involve a number of risks and uncertainties which could cause actual
results or events to differ materially from those presently anticipated.
Forward looking statements in this action may be identified through the use
of words such as “expects’”, “will,” “anticipates,”
“estimates, “believes,” or that by statements indicating certain
actions “may,” “could,” or “might” occur.
THE
READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE
INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SMALL CAP
SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.
We
encourage our readers to invest carefully and read the investor information
available at the web sites of the Securities and Exchange Commission (SEC)
at: http://www.sec.gov
and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com
. Readers can review all public filings by companies at the SEC's EDGAR
page. The NASD has published information on how to invest carefully at its
web site.
|